An Open-Label, Phase 1 Safety and Phase 2 Randomized Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)

Administered By

Awarded By

Contributors

Start/End

  • July 24, 2019 - June 30, 2024